Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy
نویسندگان
چکیده
منابع مشابه
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
UNLABELLED Chimeric antigen receptor-modified (CAR) T cells targeting CD19 (CART19) have shown therapeutical activities in CD19+ malignancies. However, the etiological nature of neurologic complications remains a conundrum. In our study, the evidence of blood-brain barrier (BBB)-penetrating CAR T cells as a culprit was revealed. A patient with acute lymphocytic leukemia developed sustained pyre...
متن کاملPleural cavity cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
RATIONALE Cytokine release syndrome (CRS) is a common and potentially fatal complication of CAR-T cell therapy. However, compartment CRS is relatively rare in hematological malignancies, as well as in solid tumors. The pathogenesis and prognosis of compartment CRS are unclear and there is no standardized treatment yet. In this case report, we will introduce a patient developing pleural cavity C...
متن کاملChimeric Antigen Receptor (CAR) T-Cell Therapy.
Surgery, chemotherapy, and radiation therapy have been the foundation of cancer treatment. Advances in the field of immunology (a branch of science that studies all aspects of the immune system) have led to a greater understanding of the ways in which the body’s own defenses can be used for treatment of blood cancers. Cancer researchers are now studying how the immune system can help destroy ca...
متن کاملIdentification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.
UNLABELLED Chimeric antigen receptor (CAR)-modified T cells with anti-CD19 specificity are a highly effective novel immune therapy for relapsed/refractory acute lymphoblastic leukemia. Cytokine release syndrome (CRS) is the most significant and life-threatening toxicity. To improve understanding of CRS, we measured cytokines and clinical biomarkers in 51 CTL019-treated patients. Peak levels of ...
متن کاملTitle: Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia
Receptor T cell Therapy for Acute Lymphoblastic Leukemia Authors: David T. Teachey, MD,1,4,8* Simon F. Lacey, Ph.D,6,8,9* Pamela A. Shaw, Ph.D,3* J. Joseph Melenhorst, Ph.D,6,8,9* Shannon L. Maude, MD, PhD,1,4,8 Noelle Frey, MD,5,7,8 Edward Pequignot, MS,6,8 Vanessa E. Gonzalez, M.B.A,6,8 Fang Chen, PhD,6,8,9 Jeffrey Finklestein,6,8 David M. Barrett, MD, PhD, 1,4,8 Scott L. Weiss, MD, MSCE,2 Ju...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Haematology
سال: 2018
ISSN: 0007-1048
DOI: 10.1111/bjh.15644